Small molecule · Inhibitor of Cholesteryl ester transfer protein (CETP) · developed by NewAmsterdam Pharma
Obicetrapib is a CETP inhibitor that blocks cholesteryl ester transfer protein, a plasma protein that moves cholesteryl esters between lipoproteins. It is studied in combination with ezetimibe and with evolocumab in atherosclerotic cardiovascular disease, hypercholesterolemia and familial hypercholesterolemia.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07219602 | Phase 3 | Lipidemia | Active not recruiting | NAMS |
| NCT06305559 | Phase 3 | Lipidemia | Active not recruiting | NAMS |
| NCT06005597 | Phase 3 | Dyslipidemias | Completed | NAMS |
| NCT05202509 | Phase 3 | Atherosclerotic Cardiovascular Disease | Active not recruiting | NAMS |
| NCT06982508 | Phase 2 | Antioxidant Absorption | Recruiting | NAMS |
| NCT06496243 | Phase 2 | Dyslipidemias | Recruiting | NAMS |
| NCT04770389 | Phase 2 | Dyslipidemias | Completed | NAMS |
| NCT06250205 | Phase 1 | Healthy Volunteers | Completed | NAMS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Antioxidant AbsorptionAtherosclerotic Cardiovascular DiseaseCoronary Artery DiseaseLipidemiaMetabolic Syndrome (MetS)Plaque, AtheroscleroticType 2 Diabetes (T2DM)ASCVDDyslipidemiasFamilial HypercholesterolemiaHealthy VolunteersHigh CholesterolHypercholesterolemia
Updated Oct 25, 2026. Something wrong or missing? Report it on the NAMS page.
See NAMS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NAMS catalysts and pipeline →